Table 2:

Adjusted Hazard ratio (aHR) of treatment success using ustekinumab or TNF antagonist therapy compared to vedolizumab as second line medication upon failure of TNF antagonist treatment in the MSHS and SPARC CD cohorts.

Cohort	Second line medication	aHR [95% CI]	aHR p-value
MSHS	Ustekinumab (ref: vedolizumab)	0.89 [0.77, 1.04]	0.15
SPARC	Ustekinumab (ref: vedolizumab)	0.66 [0.54, 0.82]	<0.001
MSHS	TNF antagonist (ref: vedolizumab)	0.99 [0.86, 1.14]	0.89
SPARC	TNF antagonist (ref: vedolizumab)	0.72 [0.60, 0.87]	<0.001

Time-to-event analysis is based on IPTW-adjusted regression models using Weibull distribution.